A hepatitis B drug is U.S.-approved. In trials, 19% controlled the infection without medication.

GSK's Hibsago (bepirovirsen) received FDA approval for chronic hepatitis B in adults without cirrhosis. The approval is based on Phase 3 trial results showing a 19% functional cure rate. GSK licensed the drug from Ionis and is pursuing regulatory submissions globally. GSK's stock closed at $50.63, up 2.37%.

GSK's Hibsago (bepirovirsen), licensed from Ionis, received FDA approval for treating chronic hepatitis B (CHB). The drug, showing 19% functional cure rates in trials, is used with NrtI therapy. Ionis may receive milestone payments and royalties. GSK is pursuing regulatory approvals globally. Bepirovirsen has Breakthrough Therapy and Priority Review designations in the U.S., China, and Japan.

Hutchmed (00013.HK) finalized a licensing deal with GSK for its KRAS-EGFR conjugate therapy, HMPL-A830. GSK gains global rights (excluding Greater China) for $110M upfront, with up to $1.185B in milestones. Hutchmed leads Phase I trials, while GSK handles later stages. The drug targets cancers with KRAS mutations, currently in early clinical testing.

GSK's depemokimab (Exdensur) showed significant improvements in asthma patients' quality of life, with benefits seen as early as 4 weeks and persisting through 52 weeks, according to a study presented at the CHEST Annual Meeting. The treatment was administered subcutaneously twice a year, with 363 patients receiving 100 mg doses and 196 on placebo. Mean changes in symptom, activity, and impact scores on the St.

GSK (NYSE: GSK) received FDA approval for Hibsago, a treatment for chronic hepatitis B. The company offers a 3.49% dividend yield with a 39% payout ratio and a 2.5% 3-year dividend growth rate. GSK's stock is trading at $50.63, 9.8% above its GF Value of $46.13. The company has a GF Score of 77/100, indicating solid financial health and valuation.

GSK plc (GSK) received FDA approval for Hibsago (bepirovirsen) to treat certain adult chronic hepatitis B patients. The drug is approved for use with NrtI therapy in patients without cirrhosis and with HBsAg ≤3000 IU/mL, following at least 6 months of NrtI treatment and suppressed HBV DNA. This marks GSK's second country approval for the drug, following Japan.